Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

被引：0

作者：

Chen, Guoping ^{[1
,2
]}

Ou, Jianghua ^{[1
]}

Liu, Jun ^{[3
]}

Liao, Haoran ^{[2
]}

Ding, Linwei ^{[2
]}

Fan, Pingming ^{[2
]}

Du, Guankui ^{[2
,3
,4
,5
,6
]}

机构：

[1] Xinjiang Med Univ, Dept Breast Surg, Affiliated Tumor Hosp, Urumqi, Peoples R China

[2] Hainan Med Univ, Dept Breast Surg, Affiliated Hosp 1, Haikou, Peoples R China

[3] Hainan Med Univ, Dept Immunol, Haikou, Peoples R China

[4] Hainan Med Univ, Key Lab Mol Biol, Haikou, Peoples R China

[5] Hainan Med Univ, Dept Biochem & Mol Biol, Haikou, Peoples R China

[6] Hainan Med Univ, Biotechnol & Biochem Lab, Haikou, Peoples R China

来源：

FRONTIERS IN MEDICINE | 2022年 / 9卷

关键词：

breast cancer; HER2; trastuzumab; dramatic thrombocytopenia; complement response; P-SELECTIN; EMTANSINE; SYSTEM;

D O I：

10.3389/fmed.2022.1037493

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundThe usual treatment option for HER2 breast cancer is targeted therapy with trastuzumab. The common adverse effects of trastuzumab treatment are thrombocytopenia, however, acute thrombocytopenia is rare and its mechanism is still largely unknown. Case presentationWe reported a patient who presented with acute thrombocytopenia on two consecutive occasions, and the predisposing factor was identified on the second occasion because of trastuzumab-only treatment. Routine blood results showed a dramatic increase in white blood cell count and neutrophil count after both trastuzumab treatments. Moreover, the complement reaction results suggested that the dramatic thrombocytopenia was probably due to platelet destruction after complement activation. ConclusionThis case suggests that it would be useful to perform a platelet complement reaction test before trastuzumab treatment in patients with HER2 breast cancer.

引用

页数：5

共 37 条

[1] The role of the complement system in cancer [J].

Afshar-Kharghan, Vahid .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (03) :780-789

[2] Plasmapheresis in a Case of Acute Kidney Injury with Severe Hemolysis and Thrombocytopenia due to Hematotoxic (Russell's viper) Snake Bite [J].

Arora, Puneet ;

Belwal, Shantanu ;

Uniyal, Bhupesh ;

Saxena, Sanjay .

SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2020, 31 (01) :276-280

[3] A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer [J].

Bender, Brendan C. ;

Schaedeli-Stark, Franziska ;

Koch, Reinhold ;

Joshi, Amita ;

Chu, Yu-Waye ;

Rugo, Hope ;

Krop, Ian E. ;

Girish, Sandhya ;

Friberg, Lena E. ;

Gupta, Manish .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) :591-601

[4] Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].

Bloom, Meghan J. ;

Song, Patrick N. ;

Virostko, John ;

Yankeelov, Thomas E. ;

Sorace, Anna G. .

CANCERS, 2022, 14 (17)

[5] Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials [J].

Cargnin, Sarah ;

Shin, Jae Il ;

Genazzani, Armando A. ;

Nottegar, Alessia ;

Terrazzino, Salvatore .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (05) :577-588

[6] Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial [J].

Ciruelos, Eva ;

Villagrasa, Patricia ;

Pascual, Tomas ;

Oliveira, Mafalda ;

Pernas, Sonia ;

Pare, Laia ;

Escriva-de-Romani, Santiago ;

Manso, Luis ;

Adamo, Barbara ;

Martinez, Eduardo ;

Cortes, Javier ;

Vazquez, Silvia ;

Perello, Antonia ;

Garau, Isabel ;

Mele, Mireia ;

Martinez, Noelia ;

Montano, Alvaro ;

Bermejo, Begona ;

Morales, Serafin ;

Echarri, Maria J. ;

Vega, Estela ;

Gonzalez-Farre, Blanca ;

Martinez, Debora ;

Galvan, Patricia ;

Canes, Jordi ;

Nuciforo, Paolo ;

Gonzalez, Xavier ;

Prat, Aleix .

CLINICAL CANCER RESEARCH, 2020, 26 (22) :5820-5829

[7] Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines [J].

Collins, D. M. ;

O'Donovan, N. ;

McGowan, P. M. ;

O'Sullivan, F. ;

Duffy, M. J. ;

Crown, J. .

ANNALS OF ONCOLOGY, 2012, 23 (07) :1788-1795

[8] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer [J].

Dieras, Veronique ;

Bachelot, Thomas .

TARGETED ONCOLOGY, 2014, 9 (02) :111-122

[9] Neutrophil Extracellular Trap (NET) Impact on Deep Vein ThrombosisTobias [J].

Fuchs, Tobias A. ;

Brill, Alexander ;

Wagner, Denisa D. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (08) :1777-1783

[10] Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer [J].

Gao, Chundi ;

Li, Huayao ;

Zhou, Chao ;

Liu, Cun ;

Zhuang, Jing ;

Liu, Lijuan ;

Sun, Changgang .

FRONTIERS IN ENDOCRINOLOGY, 2022, 13

← 1 2 3 4 →